

CJASN

Clinical Journal of the American Society of Nephrology

September 2016 • Vol. 11 • No. 9

Editorials

- 1515 Urinary Angiotensinogen: A Promising Biomarker of AKI Progression in Acute Decompensated Heart Failure: What Does It Mean?**
Jan Wysocki and Daniel Battle
See related article on page 1536.
- 1518 What Is the Correct Approach for Comparing GFR by Different Methods across Levels of GFR?**
Andrew D. Rule and Walter K. Kremers
See related article on page 1574.
- 1522 Assisted Peritoneal Dialysis as an Alternative to In-Center Hemodialysis**
Edwina A. Brown and Martin Wilkie
See related article on page 1606.
- 1525 Pragmatic, Precision Medicine Approaches for Dialysis Vascular Access Dysfunction: Challenges and Opportunities**
Prabir Roy-Chaudhury
See related article on page 1615.

Original Articles

- Acute Kidney Injury**
- 1527 Acute Kidney Injury Urine Biomarkers in Very Low-Birth-Weight Infants**
David J. Askenazi, Rajesh Koralkar, Neha Patil, Brian Halloran, Namasivayam Ambalavanan, and Russell Griffin
- 1536 Urinary Biomarkers at the Time of AKI Diagnosis as Predictors of Progression of AKI among Patients with Acute Cardiorenal Syndrome**
Chunbo Chen, Xiaobing Yang, Ying Lei, Yan Zha, Huafeng Liu, Changsheng Ma, Jianwei Tian, Pingyan Chen, Tiecheng Yang, and Fan Fan Hou
See related editorial on page 1515.
- Chronic Kidney Disease**
- 1546 Inflammation and Progression of CKD: The CRIC Study**
Richard L. Amdur, Harold I. Feldman, Jayanta Gupta, Wei Yang, Peter Kanetsky, Michael Shlipak, Mahboob Rahman, James P. Lash, Raymond R. Townsend, Akinlolu Ojo, Akshay Roy-Chaudhury, Alan S. Go, Marshall Joffe, Jiang He, Vaidyanathapuram S. Balakrishnan, Paul L. Kimmel, John W. Kusek, Dominic S. Raj, and the CRIC Study Investigators
- 1557 Silent Cerebral Microbleeds and Longitudinal Risk of Renal and Cardiovascular Events in Patients with CKD**
Hideaki Shima, Tatsuhiko Mori, Masayuki Ooi, Mika Sonoda, Tetsuo Shoji, Eiji Ishimura, Mikio Okamura, Nobukazu Ishizaka, and Masaaki Inaba
- 1566 Variation in Patients' Awareness of CKD according to How They Are Asked**
Delphine S. Tuot, Yunnuo Zhu, Alexandra Velasquez, Juan Espinoza, C. Damaris Mendez, Tanushree Banerjee, Chi-yuan Hsu, and Neil R. Powe
- 1574 Measurement Error as Alternative Explanation for the Observation that CrCl/GFR Ratio is Higher at Lower GFR**
Xuehan Zhang, Charles E. McCulloch, Feng Lin, Yen-chung Lin, Isabel Elaine Allen, Nisha Bansal, Alan S. Go, and Chi-yuan Hsu
See related editorial on page 1518.

Clinical Immunology and Pathology

- 1582 Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis**
Yi-miao Zhang, Qiu-hua Gu, Jing Huang, Zhen Qu, Xin Wang, Li-qiang Meng, Fang Wang, Gang Liu, Zhao Cui, and Ming-hui Zhao

Epidemiology and Outcomes

- 1590 Risk Factors for and Outcomes of Catheter-Associated Peritonitis in Children: The SCOPE Collaborative**
Christine B. Sethna, Kristina Bryant, Raj Munshi, Bradley A. Warady, Troy Richardson, John Lawlor, Jason G. Newland, and Alicia Neu on behalf of the SCOPE Investigators

ESRD and Chronic Dialysis

- 1597 Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis**
Geoffrey A. Block, David P. Rosenbaum, Maria Leonsson-Zachrisson, Bergur V. Stefansson, Tina Rydén-Bergsten, Peter J. Greasley, Susanne A. Johansson, Mikael Knutsson, and Björn C. Carlsson

- 1606 Hospitalization Rates for Patients on Assisted Peritoneal Dialysis Compared with In-Center Hemodialysis**
Matthew J. Oliver, Ahmed A. Al-Jaishi, Stephanie N. Dixon, Jeffrey Perl, Arsh K. Jain, Susan D. Lavoie, Danielle M. Nash, J. Michael Paterson, Charmaine E. Lok, and Robert R. Quinn
See related editorial on page 1522.

- 1615 Preoperative Vascular Medial Fibrosis and Arteriovenous Fistula Development**
Yan-Ting Shiu, Silvio H. Litovsky, Alfred K. Cheung, Daniel B. Pike, Jason Chieh Sheng Tey, Yingying Zhang, Carlton J. Young, Michelle Robbin, Kenneth Hoyt, and Michael Allon
See related editorial on page 1525.

Geriatric Nephrology

- 1624 Functional and Cognitive Impairment, Frailty, and Adverse Health Outcomes in Older Patients Reaching ESRD—A Systematic Review**
Marije H. Kallenberg, Hilda A. Kleinveld, Friedo W. Dekker, Barbara C. van Munster, Ton J. Rabelink, Marjolijn van Buren, and Simon P. Mooijaart

Renal Transplantation

- 1640 Creatinine-Based and Cystatin C-Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients**
Mira T. Keddis, Hatem Amer, Nikolay Voskoboev, Walter K. Kremers, Andrew D. Rule, and John C. Lieske
- 1650 Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate**
Bekir Tanriover, Vishal Jaikaransingh, Malcolm P. MacConmara, Justin R. Parekh, Swee-Ling Levea, Venkatesh K. Ariyamuthu, Song Zhang, Ang Gao, Mehmet U.S. Ayvaci, Burhaneddin Sandikci, Nilum Rajora, Vaqar Ahmed, Christopher Y. Lu, Sumit Mohan, and Miguel A. Vazquez

Glomerular Disease Update for the Clinician

- 1662 Introduction: Glomerular Disease Update for the Clinician**
Carla M. Nester and Ronald J. Falk
- 1664 The Players: Cells Involved in Glomerular Disease**
A. Richard Kitching and Holly L. Hutton

Commentary

- 1675 Chemistry Testing on Plasma Versus Serum Samples in Dialysis Patients: Clinical and Quality Improvement Implications**
Roger Neill Carey, Chinu Jani, Curtis Johnson, Jim Pearce, Patricia Hui-Ng, and Eduardo Lacson

Mini-Reviews

1681 Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance

Jonathan J. Hogan and Brendan M. Weiss

1693 Lower Extremity Permanent Dialysis Vascular Access

Vishal B. Parekh, Vandana D. Niyyar, and Tushar J. Vachharajani

Special Features

1703 Patient and Other Stakeholder Engagement in Patient-Centered Outcomes Research Institute Funded Studies of Patients with Kidney Diseases

Daniel Cukor, Lewis M. Cohen, Elizabeth L. Cope, Nasrollah Ghahramani, S. Susan Hedayati, Denise M. Hynes, Vallabh O. Shah, Francesca Tentori, Mark Unruh, Jeanette Bobelu, Scott Cohen, Laura M. Dember, Thomas Faber, Michael J. Fischer, Rani Gallardo, Michael J. Germain, Donica Ghahate, Nancy Grote, Lori Hartwell, Patrick Heagerty, Paul L. Kimmel, Nancy Kutner, Susan Lawson, Lisa Marr, Robert G. Nelson, Anna C. Porter, Phillip Sandy, Bruce B. Struminger, Lalita Subramanian, Steve Weisbord, Bessie Young, and Rajnish Mehrotra

1713 Alport Syndrome in Women and Girls

Judy Savige, Deb Colville, Michelle Rheault, Susie Gear, Rachel Lennon, Sharon Lagas, Moira Finlay, and Frances Flinter

Erratum

1721 Correction

On the Cover

What is the diagnosis? A 15-year-old with underlying Turner syndrome, hypothyroidism, and Guillain-Barre syndrome presented with symptoms concerning for meningitis and was treated with empiric antibiotics and intravenous acyclovir. Other medications included levothyroxine, ranitidine, furosemide and vitamin D. Kidney function remained stable; however, urinalysis revealed SG 1.020, pH 5.0, 1+ protein, 1+ glucose, and 3+ blood following acyclovir exposure. Urine sediment analysis demonstrated white blood cells, red blood cells, rare granular casts, and numerous needle shaped crystals (**left panel**), which were birefringent with polarization (**right panel**). These findings were consistent acyclovir-induced crystalluria. Acyclovir is one of a number of medications that is associated with crystal formation within the urine. Other drugs included on this list are sulfadiazine/sulfamethoxazole, indinavir, atazanavir, ciprofloxacin, methotrexate, ascorbic acid, ethylene glycol, triamterene, and amoxicillin. With these agents, either the drug or one of its metabolites may crystallize within the renal tubules. Crystal precipitation typically occurs due to one or more of the following factors: drug insolubility, high or low urine pH, sluggish urine flow rates, and underlying kidney disease. Acyclovir is unaffected by urine pH and crystal precipitation is generally driven by drug insolubility in urine when given in high, intravenous bolus doses to patients with underlying kidney disease or in the setting of volume depletion. Urinary pH plays a role for drugs such as ciprofloxacin, indinavir and atazanavir, which can precipitate in alkaline urine whereas sulfadiazine and methotrexate are insoluble in acid urine and more likely to precipitate at pH < 6.0. Clinically, patients may present clinically with asymptomatic crystalluria, crystalline-induced AKI, or sometimes nephrolithiasis. Prevention and therapy are directed at improving urinary flow rates, stopping or dose reducing the culprit drug, and when feasible, altering urine pH to enhance drug/metabolite solubility. Recovery of kidney function with drug removal is common; however, some patients develop CKD. (*Images and text provided by José Antonio Tesser Poloni and Maria Solange Bressan Giordani, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil and Mark A. Perazella, Yale University, New Haven, Connecticut*)